FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136171303> ?p ?o ?g. }

• W3136171303 endingPage "1095" @default.
• W3136171303 startingPage "1084" @default.
• W3136171303 abstract "We evaluated study outcomes in patients enrolled in Asian regions in the phase III EMBRACA trial of talazoparib vs. chemotherapy.Patients with human epidermal growth factor receptor 2-negative germline BRCA1/2-mutated advanced breast cancer who received prior chemotherapy were randomized 2:1 to talazoparib 1 mg/day or chemotherapy (physician's choice). Primary endpoint was progression-free survival (PFS) per independent central review in the intent-to-treat (ITT) population. This post-hoc analysis evaluated efficacy/safety endpoints in the ITT population of patients enrolled in Asian regions.Thirty-three patients were enrolled at Asian sites (talazoparib, n=23; chemotherapy, n=10). Baseline characteristics were generally comparable with the overall EMBRACA population. In Asian patients, median PFS was 9.0 months (95% confidence interval [CI], 3.0 to 15.2) for talazoparib and 7.1 months (95% CI, 1.2 to not reached) for chemotherapy (hazard ratio [HR], 0.74 [95% CI, 0.22 to 2.44]). Objective response rate was numerically higher for talazoparib vs. chemotherapy (62.5% [95% CI, 35.4 to 84.8] vs. 25.0% [95% CI, 3.2 to 65.1]). Median overall survival was 20.7 months (95% CI, 9.4 to 40.1) versus 21.2 months (95% CI, 2.7 to 35.0) (HR, 1.41 [95% CI, 0.49 to 4.05]). In Asian patients, fewer grade 3/4 adverse events (AEs), serious AEs (SAEs), grade 3/4 SAEs, and AEs resulting in dose reduction/discontinuation occurred with talazoparib than chemotherapy; for talazoparib, the frequency of these events was lower in Asian patients versus overall EMBRACA population.In this subgroup analysis, talazoparib numerically improved efficacy versus chemotherapy and was generally well tolerated in Asian patients, with fewer grade 3/4 treatment-emergent AE (TEAEs), SAEs, and TEAEs leading to dose modification vs. the overall EMBRACA population." @default.
• W3136171303 created "2021-03-29" @default.
• W3136171303 creator A5015645119 @default.
• W3136171303 creator A5017925719 @default.
• W3136171303 creator A5026459010 @default.
• W3136171303 creator A5030577122 @default.
• W3136171303 creator A5053411791 @default.
• W3136171303 creator A5069050806 @default.
• W3136171303 creator A5071276908 @default.
• W3136171303 date "2021-10-15" @default.
• W3136171303 modified "2023-10-17" @default.
• W3136171303 title "Talazoparib Versus Chemotherapy in Patients with HER2-negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial" @default.
• W3136171303 cites W1984629445 @default.
• W3136171303 cites W1989006164 @default.
• W3136171303 cites W2002962154 @default.
• W3136171303 cites W2035261965 @default.
• W3136171303 cites W2041583891 @default.
• W3136171303 cites W2098737737 @default.
• W3136171303 cites W2112241575 @default.
• W3136171303 cites W2592941899 @default.
• W3136171303 cites W2597062310 @default.
• W3136171303 cites W2607840379 @default.
• W3136171303 cites W2621271973 @default.
• W3136171303 cites W2725351446 @default.
• W3136171303 cites W2762472378 @default.
• W3136171303 cites W2804413675 @default.
• W3136171303 cites W2884256577 @default.
• W3136171303 cites W2886477543 @default.
• W3136171303 cites W2945884415 @default.
• W3136171303 cites W2946519987 @default.
• W3136171303 cites W2965094510 @default.
• W3136171303 cites W2971539214 @default.
• W3136171303 cites W2988654884 @default.
• W3136171303 cites W2990079331 @default.
• W3136171303 cites W3032414508 @default.
• W3136171303 cites W3069915980 @default.
• W3136171303 cites W3088917125 @default.
• W3136171303 cites W3089539477 @default.
• W3136171303 doi "https://doi.org/10.4143/crt.2020.1381" @default.
• W3136171303 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8524025" @default.
• W3136171303 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33781053" @default.
• W3136171303 hasPublicationYear "2021" @default.
• W3136171303 type Work @default.
• W3136171303 sameAs 3136171303 @default.
• W3136171303 citedByCount "5" @default.
• W3136171303 countsByYear W31361713032021 @default.
• W3136171303 countsByYear W31361713032023 @default.
• W3136171303 crossrefType "journal-article" @default.
• W3136171303 hasAuthorship W3136171303A5015645119 @default.
• W3136171303 hasAuthorship W3136171303A5017925719 @default.
• W3136171303 hasAuthorship W3136171303A5026459010 @default.
• W3136171303 hasAuthorship W3136171303A5030577122 @default.
• W3136171303 hasAuthorship W3136171303A5053411791 @default.
• W3136171303 hasAuthorship W3136171303A5069050806 @default.
• W3136171303 hasAuthorship W3136171303A5071276908 @default.
• W3136171303 hasBestOaLocation W31361713032 @default.
• W3136171303 hasConcept C121608353 @default.
• W3136171303 hasConcept C126322002 @default.
• W3136171303 hasConcept C141071460 @default.
• W3136171303 hasConcept C143998085 @default.
• W3136171303 hasConcept C168563851 @default.
• W3136171303 hasConcept C203092338 @default.
• W3136171303 hasConcept C207103383 @default.
• W3136171303 hasConcept C2776694085 @default.
• W3136171303 hasConcept C2778715236 @default.
• W3136171303 hasConcept C2908647359 @default.
• W3136171303 hasConcept C44249647 @default.
• W3136171303 hasConcept C530470458 @default.
• W3136171303 hasConcept C71924100 @default.
• W3136171303 hasConcept C99454951 @default.
• W3136171303 hasConceptScore W3136171303C121608353 @default.
• W3136171303 hasConceptScore W3136171303C126322002 @default.
• W3136171303 hasConceptScore W3136171303C141071460 @default.
• W3136171303 hasConceptScore W3136171303C143998085 @default.
• W3136171303 hasConceptScore W3136171303C168563851 @default.
• W3136171303 hasConceptScore W3136171303C203092338 @default.
• W3136171303 hasConceptScore W3136171303C207103383 @default.
• W3136171303 hasConceptScore W3136171303C2776694085 @default.
• W3136171303 hasConceptScore W3136171303C2778715236 @default.
• W3136171303 hasConceptScore W3136171303C2908647359 @default.
• W3136171303 hasConceptScore W3136171303C44249647 @default.
• W3136171303 hasConceptScore W3136171303C530470458 @default.
• W3136171303 hasConceptScore W3136171303C71924100 @default.
• W3136171303 hasConceptScore W3136171303C99454951 @default.
• W3136171303 hasFunder F4320307765 @default.
• W3136171303 hasIssue "4" @default.
• W3136171303 hasLocation W31361713031 @default.
• W3136171303 hasLocation W31361713032 @default.
• W3136171303 hasLocation W31361713033 @default.
• W3136171303 hasLocation W31361713034 @default.
• W3136171303 hasLocation W31361713035 @default.
• W3136171303 hasOpenAccess W3136171303 @default.
• W3136171303 hasPrimaryLocation W31361713031 @default.
• W3136171303 hasRelatedWork W2039052235 @default.
• W3136171303 hasRelatedWork W2090763189 @default.
• W3136171303 hasRelatedWork W2154948599 @default.
• W3136171303 hasRelatedWork W2516062397 @default.
• W3136171303 hasRelatedWork W2792916732 @default.

• next